Skip to main content
. 2022 Jun 4;41(3):555–567. doi: 10.1200/JCO.21.02370

FIG 3.

FIG 3.

Subgroup analysis of ongoing response in the all-treated population (N = 68). BTKi, Bruton tyrosine kinase inhibitor; MCL, mantle cell lymphoma; MRD, minimal residual disease; NA, not available; PI, proliferation index; POD24, progression of disease < 24 months after initial diagnosis; TP53, tumor protein p53 gene.